Initial Therapeutics
Esraa Mohamed is currently a Scientist II at Initial Therapeutics since April 2022. Prior to this role, Esraa worked as a Postdoctoral Researcher at the University of California, San Francisco from September 2019 to April 2022. Before that, Esraa was a PhD Graduate Student at Virginia Commonwealth University School of Medicine from August 2013 to August 2019. Esraa's academic background includes a Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology from Virginia Commonwealth University School of Medicine and a Bachelor's degree in Pharmaceutical Sciences from Misr International University.
This person is not in any offices
Initial Therapeutics
Initial Therapeutics is an ATP company that develops small-molecule medicines designed to prevent pathogenic protein synthesis. The company provides an approach that is differentiated from protein degradation and other interventions that recognize and tackle proteins only after they are fully formed for medical needs.